TABLE 4.
Cross-reactivity of the Onsite dengue IgG RDT for other diseases or special conditions in the additional cross-reactivity panel
| Disease/condition | N | Cross-reactivity, n (%) |
|---|---|---|
| Antinuclear antibodies | 13 | 0 (0) |
| Borrelia (Lyme) | 12 | 0 (0) |
| Chikungunya | 19 | 0 (0) |
| Cytomegalovirus | 12 | 0 (0) |
| SARS-CoV-2 | 36 | 1 (2.8) |
| Epstein-Barr virus | 13 | 0 (0) |
| Enterovirus | 15 | 0 (0) |
| Human anti-murine antibody | 15 | 0 (0) |
| Hepatitis A | 11 | 0 (0) |
| Hepatitis B | 16 | 0 (0) |
| Hepatitis C | 18 | 0 (0) |
| Human immunodeficiency virus 1/2 | 36 | 1 (2.8) |
| Herpes simplex virus type 1 | 10 | 0 (0) |
| Herpes simplex virus type 2 | 11 | 0 (0) |
| Influenza A | 17 | 0 (0) |
| Influenza B | 15 | 0 (0) |
| Leptospirosis | 12 | 1 (8.3) |
| Malaria | 20 | 0 (0) |
| Measles | 23 | 0 (0) |
| Parvovirus B19 | 12 | 0 (0) |
| Rheumatoid Factor | 14 | 0 (0) |
| Rubella | 23 | 1 (4.3) |
| Syphilis | 12 | 0 (0) |
| Varicella-zoster virus | 12 | 1 (8.3) |